Genenta Science SpA Sponsored ADR (GNTA) Price & Analysis

Compare

22 Followers

GNTA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.74 - $7.28

Previous Close$5.5

Volume13.55K

Average Volume (3M)19.01K

Market Cap

$69.14M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta-0.26

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.53

Shares Outstanding18,289,865

10 Day Avg. Volume3,088

30 Day Avg. Volume19,011

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$25.00

Price Target Upside575.68% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsData from the ongoing P1/2 program for GBM has demonstrated 2-year survival rates of 25%, exceeding historical control of ~15%.

Market OpportunitiesTemferon demonstrating potential across multiple indications could open the door to substantial market opportunities, particularly as it addresses areas with significant unmet medical need.

Regulatory ApprovalGenenta receives approval to initiate a Phase 1 clinical trial for Temferon in metastatic renal cell cancer, marking a key milestone as it expands Temferon’s application into a new therapeutic area.

Bears Say

Clinical TrialsThe P1 pilot trial in mRCC is expected to be a very important study in terms of demonstrating Temferon's ability to alter the tumor microenvironment (TME) in the clinic.

Program ExpansionThere are expectations for additional updates in their Glioblastoma program.

Genenta Science SpA Sponsored ADR News

Genenta Science S.p.A. to Terminate Dedicated Suite Agreement with AGC Biologics

Genenta Science SpA Sponsored ADR ( ($GNTA) ) just unveiled an announcement. On December 30, 2024, Genenta Science...

7d ago

GNTA

Promising Long-Term Data and New Trials Bolster Genenta Science’s Buy Rating

Genenta Science SpA Sponsored ADR, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst...

1M ago

GNTA

Genenta Science announces follow-up observations in glioblastoma study

Genenta Science (GNTA) announced that a total of 38 patients were enrolled in newly diagnosed glioblastoma multiforme study,...

1M ago

GNTA

Genenta Science, Anemocyte announce collaboration

Genenta Science (GNTA) announced a collaboration with Anemocyte. This strategic partnership marks a major milestone, encompassing the successful...

3M ago

GNTA

Genenta Science Secures €20 Million Financing to Boost Cancer Therapy Development

Genenta Science SpA Sponsored ADR ( ($GNTA) ) has issued an announcement. On March 19, 2025, Genenta Science...

5M ago

GNTA

Genenta Science Secures €20 Million Convertible Bond Financing for Oncology Research

The latest announcement is out from Genenta Science SpA Sponsored ADR ( ($GNTA) ). On March 12, 2025,...

5M ago

GNTA

Genenta Science announces EUR 20M financing to expand pipeline

Genenta announced a EUR 20M financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and...

5M ago

GNTA

Genenta Science announces amendment to pact with AGC Biologics

Genenta Science (GNTA) announced that it has strengthened its partnership with contract development and manufacturing organization AGC Biologics...

7M ago

GNTA

Genenta Science Enhances Manufacturing Agreement with AGC Biologics

Genenta Science SpA Sponsored ADR ( ($GNTA) ) just unveiled an announcement. Genenta Science S.p.A. and AGC Biologics...

7M ago

GNTA

Genenta Science Updates ATM Sales Agreement with New Agent

An update from Genenta Science SpA Sponsored ADR ( ($GNTA) ) is now available. Genenta Science S.p.A. has...

8M ago

GNTA

Genenta Science SPA (ADR) trading resumes

09:40 EST Genenta Science (GNTA) SPA (ADR) trading resumes Published first on TheFly – the ultimate source for...

8M ago

GNTA

Genenta Science SPA (ADR) trading halted, volatility trading pause

09:30 EST Genenta Science (GNTA) SPA (ADR) trading halted, volatility trading pause Published first on TheFly – the...

8M ago

GNTA

Genenta Science CEO to present at U.S. Senate meeting

Genenta Science (GNTA) announced that Pierluigi Paracchi, CEO, will attend as a speaker to the Italy-U.S. meeting “Cross-Border...

10M ago

GNTA

Genenta Science SPA (ADR) trading resumes

09:35 EDT Genenta Science (GNTA) SPA (ADR) trading resumes Published first on TheFly – the ultimate source for...

10M ago

GNTA

GNTA FAQ

What was Genenta Science SpA Sponsored ADR’s price range in the past 12 months?

Genenta Science SpA Sponsored ADR lowest stock price was $2.74 and its highest was $7.28 in the past 12 months.

What is Genenta Science SpA Sponsored ADR’s market cap?

Genenta Science SpA Sponsored ADR’s market cap is $69.14M.

When is Genenta Science SpA Sponsored ADR’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Genenta Science SpA Sponsored ADR’s earnings last quarter?

Currently, no data Available

Is Genenta Science SpA Sponsored ADR overvalued?

According to Wall Street analysts Genenta Science SpA Sponsored ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Genenta Science SpA Sponsored ADR pay dividends?

Genenta Science SpA Sponsored ADR does not currently pay dividends.

What is Genenta Science SpA Sponsored ADR’s EPS estimate?

Genenta Science SpA Sponsored ADR’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Genenta Science SpA Sponsored ADR have?

Genenta Science SpA Sponsored ADR has 18,289,865 shares outstanding.

What happened to Genenta Science SpA Sponsored ADR’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Genenta Science SpA Sponsored ADR?

Currently, no hedge funds are holding shares in GNTA

Genenta Science SpA Sponsored ADR Stock Smart Score

Neutral

Fundamentals

Return on Equity

-54.30%

Trailing 12-Months

Asset Growth

-37.82%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Genenta Science SpA Sponsored ADR

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.

Genenta Science SpA Sponsored ADR (GNTA) Earnings & Revenues

Currently, no data available

Please return soon. This page is being updated.

Historic Earnings Reports

GNTA Stock 12 Month Forecast

Average Price Target

$25.00

▲(575.68% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","8":"$8","14":"$14","20":"$20","26":"$26"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8,14,20,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2023","6":"Jun<br/>2023","9":"Apr<br/>2024","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.82,5.449230769230769,7.078461538461538,8.707692307692307,10.336923076923076,11.966153846153846,13.595384615384615,15.224615384615385,16.853846153846153,18.483076923076922,20.11230769230769,21.74153846153846,23.37076923076923,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.82,5.449230769230769,7.078461538461538,8.707692307692307,10.336923076923076,11.966153846153846,13.595384615384615,15.224615384615385,16.853846153846153,18.483076923076922,20.11230769230769,21.74153846153846,23.37076923076923,{"y":25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.82,5.449230769230769,7.078461538461538,8.707692307692307,10.336923076923076,11.966153846153846,13.595384615384615,15.224615384615385,16.853846153846153,18.483076923076922,20.11230769230769,21.74153846153846,23.37076923076923,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.31,"date":1656633600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.98,"date":1664582400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1672531200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1675209600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.35,"date":1677628800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.94,"date":1680307200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.51,"date":1685577600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.89,"date":1688169600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.61,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.08,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >